OK, looking at S-1......
8 million shares, bringing the total to about 28? Bit rich for me at $/share significantly less than they're talking about.
I looked at the search report for WO 00036106A3. While it looks bad, the stuff referenced doesn't look like prior art to me..... visualizing stuff in see-through worms, etc. The claim language is broad, but.... sorry, this looks very complex to me........ it would take a long time to evaluate the potential that DGEN/ABSC etc. might be excluded from practicing a similar art.
Looks like DNX is almost paying for itself?
The mice and their evaluative capacities look to be *the* product. For that reason, I'd bet that, without another indiscriminate rally, it's not going to go anywhere fast. Among the "phenotyping" companies, I like one that has a product ("drug") focus.
But..... again..... this isn't a simple evaluation. Maybe it would be simple for someone else, but I doubt it.
Tom posted some of the comments by Ben Holmes, where he said "There are no significant VCs behind the company".
What does he think this is, chopped liver?.........
(3) In January 1998, we sold an aggregate of 5,041,539 shares of Series C
preferred stock at a price of $1.30 per share to ten accredited
investors, including Brentwood Affiliates Fund, Brentwood Associates
VIII, L.P., David W. Carter, Delphi BioInvestments IV, L.P., Delphi
Ventures IV, L.P., and Harvard Private Capital Holdings, Inc. These
transactions were exempt from registration in reliance on Regulation D
under the Securities Act.
(4) In April 1999, we sold an aggregate of 6,678,791 shares of Series D
preferred stock at a price of $1.65 per share to fourteen accredited
investors, including Brentwood Affiliates Fund, Brentwood Associates
VIII, L.P., Delphi BioInvestments IV, L.P., Delphi Ventures IV, L.P.,
Harvard Private Capital Holdings, Inc., Invemed Fund, L.P., Invemed
Associates LLC, and S.R. One, Ltd. These transactions were exempt from
registration in reliance on Regulation D under the Securities Act.
(5) In May 2000, we sold an aggregate of 7,194,113 shares of Series E
preferred stock at a price of $4.25 per share to thirteen accredited
investors, including Brentwood Associates VIII, L.P., Chevron
Technology Ventures LLC, Delphi BioInvestments IV, L.P., Delphi
Ventures IV., L.P., Harvard Private Capital Holdings, Inc., HSBC
Investment Bank Plc, Invemed Fund, L.P., Lombard Oldier + Cie, and S.R.
One, Ltd. These transactions were exempt from registration in reliance
on Regulation D under the Securities Act.
Silly me. I thought that I had heard of a few of these groups. |
